| Check Point Software Technologies Ltd | 113.7700 / +0.21% |
| Date/Time | 12/12 / 22:00 |
| Chg. / Chg.(%) | 0.2400 / +0.21% |
| Bid | 112.1300 / 100 |
| Ask | 115.7900 / 100 |
| Open | 113.3400 |
| Previous Close | 113.5300 |
| High | 115.0650 |
| Low | 112.9000 |
| Volume [USD] | 72,218,366.6289 |
| Volume [Units] | 948,401 |
| Price fixings | 3727 |
| ISIN | IL0010824113 |
| Security | CHKP |
| Exchange | NASDAQ |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| TradeGate | 102.460 |  |
71 |
| Frankfurt | 102.0800 | |
0 |
| München | 102.14 | |
0 |
| Berlin | 102.34 | |
0 |
| Hamburg | 102.14 | |
0 |
| Düsseldorf | 101.94 | |
0 |
| Vienna Globa.. | 102.38 | |
0 |
| Lang & Schwa.. | 102.200 | |
|
| gettex | 102.360 | |
|
| Stuttgart | 102.140 | |
|
| NASDAQ | 113.7700 | |
948,401 |
| Cboe US | 113.83 | 38,618 | |
| IEX | 113.81 | |
28,360 |
| London Inter.. | 113.40 | 574 |
News
- Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
12/12/2019 / 14:30 - GlobeNewswire - Provectus Announces Presentation of Preliminary Results from Phase 1 Trial of PV-10® (rose bengal disodium) for Treatment of Metastatic Uveal Melanoma at ESMO I-O Congress 2019
12/12/2019 / 14:00 - GlobeNewswire - iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDA®
12/12/2019 / 13:00 - GlobeNewswire - Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE
12/12/2019 / 11:05 - GlobeNewswire - iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDA®
12/12/2019 / 08:00 - GlobeNewswire
Real-time